Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells

Authors
Park, Jung-JinYi, Jae YounJin, Yeung BaeLee, Yoon-JinLee, Jae-SeonLee, Yun-SilKo, Young-GyuLee, Minyoung
Issue Date
1-4월-2012
Publisher
PERGAMON-ELSEVIER SCIENCE LTD
Keywords
ST6Gal I; EGFR; Colon cancer; Gefitinib; Sialylation
Citation
BIOCHEMICAL PHARMACOLOGY, v.83, no.7, pp.849 - 857
Indexed
SCIE
SCOPUS
Journal Title
BIOCHEMICAL PHARMACOLOGY
Volume
83
Number
7
Start Page
849
End Page
857
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/108749
DOI
10.1016/j.bcp.2012.01.007
ISSN
0006-2952
Abstract
beta-Galactoside alpha 2,6-sialyltransferase (ST6Gal-I) has been shown to catalyze alpha 2,6 sialylation of N-glycan, an action that is highly correlated with colon cancer progression and metastasis. We have recently demonstrated that ST6Gal-I-induced alpha 2,6 sialylation is critical for adhesion and migration of colon cancer cells. Increase of alpha 2,6 sialylation also contributes to radioresistance of colon cancer. A number of studies have focused on the involvement of sialylation in tumorigenesis, but the mechanism underlying ST6Gal-I-induced cancer progression and the identity of enzyme substrates has received scant research attention. To provide further support for the relevance of ST6Gal-I in the malignancy of colon cancer, we prepared and characterized a ST6Gal-I-knockdown SW480 colorectal carcinoma cell line. We found that inhibition of ST6Gal-I expression increased cell proliferation and tumor growth in vitro and in vivo. An examination of the effect of sialylation on epidermal growth factor receptor (EGFR) activity and downstream signaling, which are highly correlated with cell proliferation, showed that the loss of ST6Gal-I augmented EGF-induced EGFR phosphorylation and activation of extracellular signal-regulated kinase (ERK) in colon cancer cells. Moreover, ST6Gal-I induced sialylation of both wild type and mutant EGFR. These studies provide the first demonstration that ST6Gal-I induces EGFR sialylation in human colon cancer cell lines. Importantly, the anticancer effect of the EGFR kinase inhibitor, gefitinib, was increased in ST6Gal-I-deficient colon cancer cells. In contrast, overexpression of ST6Gal I decreased the cytotoxic effect of gefitinib. These results suggest that sialylation of the EGFR affects EGF-mediated cell growth and induces chemoresistance to gefitinib in colon cancer cells. Crown Copyright (c) 2012 Published by Elsevier Inc. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
Graduate School > Department of Life Sciences > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Ko, Young Gyu photo

Ko, Young Gyu
분자생명과학과
Read more

Altmetrics

Total Views & Downloads

BROWSE